Like the Pfizer and Moderna vaccines, the COVID-19 vaccine candidate being developed by the mid-cap biotech featured in today’s article uses a messenger RNA (mRNA) platform. Unlike the Pfizer and Moderna vaccines, its candidate only requires one dose and the manufacturing process is expected to be much easier. For more on this stock that the author believes “investors should buy now if they are looking for coronavirus vaccine companies on the cheap,” CLICK HERE.
Is This One-Dose mRNA COVID Vaccine Stock A Must-Buy?
- by RobH